• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

S2Medical
Download the release

S2Medical AB (publ) (the "Company") has today concluded a manufacturing agreement for Epiprotect with the Company's distribution partner in Saudi Arabia, Arabian Trade House (ATH). The agreement provides an upfront sum of approximately SEK 2.2 million which can then be called from in the form of finished products or raw material for final packaging. Manufacturing will take place through ATH's manufacturing arm Arabian House for Industries (AHI). The agreement gives AHI an exclusive right to manufacture products for the Saudi market, which may be extended to more countries in the MENA region. Furthermore, the agreement contains obligations for orders amounting to a total of SEK 14 million over the next 3 years and an increase of at least 20% per year for subsequent years in order to retain the manufacturing right. Provided that the terms of the agreement are followed, the agreement runs for over 15 years.

The manufacturing only includes final packaging of individual products from raw materials and thus does not affect knowledge about the manufacturing of the material for Epiprotect, which will continue to be protected as a company secret and manufactured at the Company's factory in Linköping. As previously mentioned, AHI's production will only be supplied to the Saudi market with a potential option for the countries in the MENA region, which, where appropriate, will be regulated in a separate agreement. Costs for setting up the local production facility will be borne by AHI.

"Local production steps have become an important part of being able to take larger market shares in Saudi Arabia. Since the signing of the distribution agreement, ATH and AHI have proven to be a stable and reliable partner in the region and we are very much looking forward to deepening our cooperation." says the company's CEO Petter Sivlér

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-06-2023 17:15 CET.